Inhibikase Therapeutics, Inc. IKT 深 沪
已收盘 07-24 16:00:00 美东时间
2.33
0.000
0.00%
华盛通- 最 高2.53
- 今 开2.37
- 成交量 215.84万股
- 最 低 2.32
- 昨 收 2.33
- 总市值 3.66亿
- 52周最高 2.53
- 市盈率 静 --
- 换手率 1.37%
- 52周最低 1.33
- 委 比 45.19%
- 总股本 1.57亿
- 历史最高 70.80
- 量 比 1.90
- 振 幅 9.01%
- 历史最低 1.12
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to its lead p...
07-23 20:03
Inhibikase Therapeutics Sells 25M Common Shares To RA Capital Management Through At-The-Market Facility For Gross Proceeds Of $50M
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the...
07-14 20:06
美股夜盘 | Q32 Bio Inc涨37.20%，Sky Quarry, Inc.涨16.35%
Stratus Properties涨-16.01%；Inhibikase Therapeutics, Inc.涨-14.71%；环球墨非AI涨-12.69%
07-13 08:05
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5
Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating and announces Price Target of $5.
06-11 02:02
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share
05-13 04:37
Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatment Of Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), announced today that the first patient has
04-07 20:03
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share
03-27 04:04
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.
03-04 20:53
